Kactus Bio Supports Global First mRNA-based Shingles Vaccine ABO1108 Entering Phase III Clinical Trial with GMP-grade Enzyme Portfolio
Abogen
Nucleic Acid Drug Developer
Warm Congratulations to Our Strategic PartnerAbogen, its independently developed ABO1108, the world’s first mRNA-based herpes zoster vaccine, officially advanced to the multicenter Phase III clinical trial stage on June 16, 2026. ABO1108 utilizes Abogen’s proprietary base-modification technology and lipid nanoparticle (LNP) delivery system, combined with a mature lyophilized formulation process, enabling stable storage for three years at 2–8°C, thereby offering excellent stability, convenient storage, and improved accessibility.This is the world's first herpes zoster mRNA vaccine to enter Phase III clinical trials.This milestone achievement not only marks a significant breakthrough for Abogen in the industrialization of mRNA technology, but also leaves an innovative imprint of China’s biopharmaceutical sector on the global landscape of herpes zoster prevention.
Kactus Biosystems was deeply involved throughout the entire ABO1108 project, leveraging its compliant and comprehensive GMP production and quality management system to ensure a stable supply of high-quality GMP-grade mRNA IVT raw material enzymes, thereby providing robust support for Abogen’s pipeline advancement. Kactus Biosystems’ GMP-grade raw material enzymes feature three core advantages:
High Enzyme Activity & Superior Quality: GMP-grade raw material enzymes feature high purity and high activity, which can enhance mRNA product yield and effectively alleviate the burden on downstream purification processes.
Stability and Inter-batch Consistency: To meet the demands of large-scale, multi-center clinical trials, we strictly adhere to GMP manufacturing standards and comply with stringent regulatory requirements, ensuring consistent product performance and high reproducibility across all batches.
Supply Chain Resilience and Cost Optimization: Leveraging large-scale production and efficiency, we help partner companies effectively control R&D costs while ensuring a stable supply of core raw materials, thereby safeguarding the continuity of clinical trials.
Currently, Kactus Biosystems’ robust quality management system has successfully passed on-site audits conducted by dozens of biopharmaceutical companies worldwide. Its product quality strictly adheres to relevant regulations, ensuring the compliance and data traceability of every batch of GMP-grade raw material enzymes. In the fields of mRNA vaccines and cell and gene therapy (CGT), Kactus Biosystems’ GMP raw material enzyme series has helped numerous partner companies secure clinical trial approvals for their pipelines, with multiple R&D pipelines successfully advancing to Phase II and III clinical trials and accelerating toward commercialization. As a key supplier of critical raw materials for biopharmaceuticals, Kactus Biosystems will continue to increase its investment, driven by technological innovation and grounded in global compliance, working hand in hand with partners to build a high-quality ecosystem for the biopharmaceutical industry and making unremitting efforts to benefit more patients through improved health outcomes.
